BCCCP: Management of Secretions (Death Rattle)

Question 1 of 10

1. Question

A 72-year-old unresponsive man with metastatic lung cancer in the ICU is experiencing a distressing “death rattle” from noisy, gurgling respiratory secretions. The team wants rapid relief of secretions with minimal central nervous system side effects. Which of the following is the most appropriate initial pharmacologic choice?

Glycopyrrolate 0.2 mg subcutaneous every 4 hours as needed
Atropine 0.4 mg intravenous every 4 hours as needed
Scopolamine transdermal patch 1.5 mg every 72 hours
Ipratropium bromide nebulizer 500 µg every 6 hours as needed

Question 2 of 10

2. Question

A 72-year-old woman in the ICU is at end-of-life and experiencing noisy respiratory secretions (“death rattle”). She has decreased consciousness, cannot swallow safely, and a do-not-resuscitate order is in place. The team wants continuous, minimally invasive control of secretions to maximize comfort. Which glycopyrrolate regimen is MOST appropriate for initial and ongoing management?

Oral glycopyrrolate solution 0.2 mg every 4 hours as needed
Intravenous glycopyrrolate 0.2 mg bolus, then continuous IV infusion at 0.6 mg/24 h
Subcutaneous glycopyrrolate 0.2 mg bolus every 4 hours as needed
Subcutaneous glycopyrrolate 0.2 mg bolus followed by continuous SC infusion at 0.6 mg/24 h via syringe driver

Question 3 of 10

3. Question

A 67-year-old man with end-stage renal disease is receiving continuous renal replacement therapy in the ICU. He is alert but has a prominent “death rattle” from pooled oropharyngeal secretions. Considering his ESRD on CRRT, which pharmacotherapy plan is MOST appropriate to reduce secretions while minimizing adverse effects?

Initiate glycopyrronium 0.2 mg IV every 4 hours as needed, with monitoring for anticholinergic effects
Administer hyoscine hydrobromide (scopolamine) 0.4 mg SC every 4 hours as needed, monitoring for sedation and anticholinergic toxicity
Provide atropine sulfate 0.4 mg IV every 4 hours as needed, with monitoring for CNS and anticholinergic side effects
Deliver ipratropium bromide 500 µg via nebulization every 4 hours as needed to reduce airway secretions

Question 4 of 10

4. Question

An 82-year-old woman with metastatic lung cancer is receiving palliative care in the ICU for end-of-life comfort. She has a pronounced “death rattle” from noisy respiratory secretions and is receiving glycopyrrolate 0.2 mg subcutaneously every 4 hours as needed. Which of the following monitoring strategies best assesses both the efficacy of glycopyrrolate in reducing secretions and the early detection of its anticholinergic toxicities?

Serial assessment of noisy respiratory secretions to confirm reduction in death rattle severity and monitoring for urinary retention or new-onset agitation
Daily oral cavity assessment for dry mouth and routine heart rate monitoring for tachycardia
Hourly respiratory rate and oxygen saturation checks
Daily bowel movement log and serial measurement of pupil size for anticholinergic effects

Question 5 of 10

5. Question

A 72-year-old man receiving comfort care develops noisy, gurgling respirations (“death rattle”) from retained secretions. He received a subcutaneous dose of glycopyrrolate 0.2 mg 2 hours ago without improvement. His vital signs are stable, and he shows no distress. Which of the following is the MOST appropriate next pharmacologic intervention?

Repeat subcutaneous glycopyrrolate 0.2 mg.
Initiate a transdermal scopolamine (hyoscine) patch.
Administer intravenous midazolam 2 mg.
Increase the propofol infusion rate.

Question 6 of 10

6. Question

A 78-year-old man with end-stage heart failure receiving comfort-focused care develops loud, gurgling respirations (“death rattle”) that are distressing to his family. He has acute kidney injury with a serum creatinine of 2.1 mg/dL (baseline 1.0 mg/dL). Which of the following pharmacotherapy plans is most appropriate to reduce his airway secretions?

Glycopyrrolate 0.2 mg IV every 4 hours
Scopolamine hydrobromide 0.3 mg SC every 4 hours
Glycopyrrolate 0.1 mg IV every 6 hours
Atropine 0.4 mg SC every 4 hours

Question 7 of 10

7. Question

A 72-year-old male with multi-organ failure secondary to septic shock is receiving maximal supportive care in the ICU. He is currently intubated and sedated but has developed a prominent “death rattle”—noisy respiratory secretions causing distress to his family. The patient’s prognosis is poor, and the multidisciplinary team is considering next steps. As the critical care pharmacist, you are asked to guide the team on how best to approach symptom management and family communication. Considering the patient’s clinical trajectory, the family’s distress, and the presence of death rattle, which of the following represents the MOST appropriate initial recommendation from the critical care pharmacist to facilitate multidisciplinary collaboration regarding the overall approach to care?

Initiate high-dose glycopyrrolate immediately to aggressively eliminate secretions and reassure the family that all symptoms are being managed.
Schedule an urgent family meeting to discuss intubation weaning and extubation, while deferring discussion of the death rattle until after this decision.
Facilitate a comprehensive multidisciplinary goals-of-care conversation with the family, emphasizing prognosis, patient values, and balancing symptom management with avoiding burdensome interventions.
Recommend a trial of chest physiotherapy and suctioning to clear the secretions, followed by a palliative care consult if symptoms persist.

Question 8 of 10

8. Question

A 78-year-old man with end-stage metastatic lung cancer is receiving comfort measures only in the ICU. He is no longer intubated and has a Glasgow Coma Scale of 8 (E2V1M5). Over the past hour, you and the team have noticed an audible “death rattle” (moist, noisy respirations) but no signs of distress; vital signs are stable (BP 120/70 mm Hg, HR 86 bpm, SpO₂ 93% on room air). Goals of care focus on maximizing comfort. As the critical care pharmacist, which supportive care measure should you prioritize discussing with the care team and family to address the death rattle?

Administer intravenous glycopyrrolate 0.2 mg every 4 hours to reduce secretions.
Apply a transdermal scopolamine patch every 72 hours to decrease salivary secretions.
Perform deep endotracheal suctioning every 30 minutes to clear airway secretions.
Elevate the head of the bed and provide reassurance to the family that the patient is comfortable.

Question 9 of 10

9. Question

A 78-year-old female with metastatic lung cancer has been transitioned to comfort-focused care and was just extubated. She now exhibits noisy, gurgling respirations (“death rattle”) due to accumulated oropharyngeal secretions. As the critical care pharmacist, which intervention should be most prioritized to reduce these secretions and align with comfort-focused goals?

Administer low-dose intravenous glycopyrrolate to reduce oropharyngeal secretions
Apply a transdermal scopolamine (hyoscine) patch
Administer inhaled albuterol via nebulizer
Initiate a low-dose continuous infusion of intravenous morphine for dyspnea relief

Question 10 of 10

10. Question

A 78-year-old, 70 kg ICU patient (history of chronic heart failure and stage 3 chronic kidney disease; baseline Cr 1.3 mg/dL, normal liver tests) is receiving a fentanyl infusion for analgesia (target RASS –1 to 0) and had a scopolamine patch applied 48 hours ago for death rattle. He was CAM-ICU–negative until 12 hours ago, when he developed new-onset agitation (RASS +2), visual hallucinations, and confusion. Vital signs remain stable (BP 130/80 mm Hg, HR 88 bpm, RR 16 breaths/min), with no evidence of infection or metabolic disturbance. Which of the following is the MOST appropriate initial pharmacologic intervention?

Discontinue the scopolamine patch and consider a low-dose antipsychotic (e.g., haloperidol) if agitation persists.
Increase the fentanyl infusion to improve comfort and reduce agitation.
Administer a benzodiazepine such as lorazepam to sedate the patient.
Administer intravenous physostigmine to reverse central anticholinergic toxicity.

Quiz Summary

Information

Results